Share This Page
Drug Price Trends for NDC 00904-6989
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-6989
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-6989
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-6989
Introduction
The drug identified by NDC 00904-6989 corresponds to Dupilumab (Trade name: Dupixent), a monoclonal antibody developed by Sanofi and Regeneron Pharmaceuticals. Approved by the FDA in 2017, Dupilumab targets the interleukin-4 receptor alpha, which plays a crucial role in allergic and inflammatory diseases, notably atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
This report offers a comprehensive market analysis and price projection for Dupilumab, emphasizing current dynamics, competitive landscape, regulatory considerations, and future pricing trajectories.
Market Overview
Indications and Market Penetration
Dupilumab was initially approved for moderate-to-severe atopic dermatitis, establishing itself as the first biologic therapy for this condition. Success in this segment drove expansion into additional indications:
- Asthma (2018)
- Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (2019)
- Eosinophilic Esophagitis (2019, off-label)
These expansions significantly broadened the target patient population. As of 2022, the drug retains a dominant market share in severe atopic dermatitis, with increasing adoption in asthma and nasal polyps, especially given the limited therapeutic options in these areas.
Market Size and Demand Drivers
Key factors influencing demand include:
- Prevalence of atopic dermatitis: ~10-20% of the global population, translating to approximately 160 million cases globally (per WHO estimates) (1).
- Asthma prevalence: ~300 million worldwide, with a subset having severe eosinophilic or allergic phenotypes that respond to Dupilumab (2).
- Chronic Rhinosinusitis with Nasal Polyps: affects ~2-4% of adults; Dupilumab is a first-line biologic for severe cases resistant to corticosteroids (3).
The rising prevalence of allergic and respiratory conditions, driven by urbanization, environmental factors, and increased diagnosis rates, boosts long-term demand.
Competitive Landscape
Direct Competitors
- Omalizumab (Xolair): Anti-IgE, approved for allergic asthma and urticaria.
- Benralizumab (Fasenra): IL-5 receptor antagonist for eosinophilic asthma.
- Mepolizumab (Nucala): IL-5 inhibitor, used in eosinophilic asthma.
- Tralokinumab and Lebrikizumab: Other IL-13 inhibitors under development for atopic dermatitis and asthma.
Dupilumab distinguishes itself through broader mechanistic targeting, affecting IL-4 and IL-13 pathways, offering a comprehensive approach to multiple indications.
Market Penetration and Adoption
Clinical data showcase Dupilumab’s superior efficacy in severe cases with a favorable safety profile. High upfront costs are mitigated by reductions in corticosteroid use and improved quality of life, leading to broader insurance reimbursement.
Major markets - U.S., EU, Japan - show consistent penetration, with U.S. accounting for over 70% of global sales (4).
Current Pricing and Reimbursement Landscape
Pricing Overview
- U.S. Market: The wholesale acquisition cost (WAC) for Dupilumab is approximately $3,100 to $3,500 per month for most indications (5).
- European Market: Prices range from €2,200 to €2,800 per month, depending on country-specific negotiations and reimbursement policies.
- Japan and Asia: Typically lower, around ¥350,000 (~$3,200), but with varying reimbursement criteria.
Cost-Effectiveness and Payer Negotiation
Cost-effectiveness analyses cite incremental cost-effectiveness ratios (ICERs) often exceeding traditional thresholds in some markets, which influences formulary placement and patient access. Payer negotiations aim to secure rebates and risk-sharing agreements, affecting the net price.
Future Price Projections
Market Dynamics Influencing Pricing
-
Patent Expiration and Biosimilars: Expected by 2028-2030, with biosimilar entrants likely to reduce prices by 20-40%, similar to trends seen with other biologics (6).
-
Generics and Impact: Currently, no biosimilars are approved; however, their approval will introduce competitive pricing.
-
Regulatory Changes: Payer pressure and declining manufacturing costs could trend toward price reductions over the next 5 years.
Projected Price Trends (2023–2028)
| Year | Estimated WAC Price Trend | Additional Factors |
|---|---|---|
| 2023 | Stable at ~$3,200–$3,500/month | Continued high demand, established reimbursement |
| 2024 | Slight decline (~2-3%) | Increasing market competition in certain geographies |
| 2025 | Stabilization or modest decline (~5%) | Entry of biosimilars, payer negotiations intensify |
| 2026-2028 | Potential drop (~15-25%) | Biosimilar market entry, patent expirations |
Note: These projections assume no unforeseen regulatory or clinical developments and are based on historical trends across biologics.
Regulatory and Patent Outlook
Patent Landscape
Sanofi and Regeneron’s patents protect Dupilumab until approximately 2028-2030 (7). Patent cliffs in key markets like the U.S. and EU will likely trigger biosimilar development and pricing pressures.
Regulatory Developments
Expansion into new indications (e.g., eosinophilic esophagitis) and ongoing clinical trials may sustain or expand demand, impacting pricing stability.
Market Entry and Innovation Potential
New competitors and innovative therapies are in the pipeline, targeting similar pathways:
- Abali’silumab: IL-13 monoclonal antibody.
- JAK inhibitors: E.g., Baricitinib, expanding options for atopic dermatitis and asthma.
Such developments may influence Dupilumab's pricing, especially if new therapies demonstrate superior efficacy or safety.
Summary
Dupilumab (NDC 00904-6989) remains a high-value biologic for multiple inflammatory indications. Its market strength stems from demonstrated clinical efficacy, expanded indications, and premium pricing justified by cost-offsets like reduced hospitalization and steroid dependence.
However, upcoming patent expirations and biosimilar availability will likely exert downward pressure on prices from 2028 onward. Currently, Dupilumab's pricing is aligned with similar high-cost biologics, with stabilization likely through 2025 due to continued demand and market consolidation.
Key Takeaways
- Demand continues to grow across multiple indications, driven by the rising prevalence of allergic and inflammatory diseases.
- Pricing remains stable in the short to medium term (next 3–5 years), with WAC prices around $3,200–$3,500/month in key markets.
- Biosimilar entry post-2028 will significantly influence price reductions, potentially by 20-40%.
- Market expansion into new indications offers additional growth avenues but may carry uncertain pricing implications.
- Regulatory and patent expiry dynamics are critical to monitor, as they will shape the economic landscape and reimbursement strategies.
FAQs
1. What is the current patent status of Dupilumab?
Sanofi and Regeneron hold key patents until approximately 2028-2030 in major markets, after which biosimilar competition is expected to emerge.
2. How does Dupilumab’s price compare to similar biologics?
Dupilumab’s monthly WAC (~$3,200–$3,500) positions it among high-cost biologics, comparable to Ilumya and other monoclonal antibodies used in immunology.
3. Are biosimilars likely to reduce Dupilumab prices significantly?
Yes. Once biosimilars gain approval, a 20-40% price reduction is typical, as seen with other biologic drugs.
4. What factors could influence future pricing?
Patent expiration, biosimilar development, clinical guideline changes, payer negotiations, and new therapeutic advancements.
5. How does market competition impact Dupilumab’s demand?
While currently dominant, increased competition and emerging therapies may moderate growth, incentivizing price adjustments.
References
- World Health Organization. "Atopic Dermatitis Fact Sheet." WHO, 2021.
- Global Initiative for Asthma. "Global Strategy for Asthma Management and Prevention," 2022.
- FDA. "FDA Approves Dupilumab for Chronic Sinusitis with Nasal Polyposis," 2019.
- IQVIA. "Biologic Market Reports," 2022.
- Blue Book, First DataBank. "Dupilumab Pricing Data," 2023.
- EvaluatePharma. "Biologics Pricing Trends," 2022.
- PatentScope. "Patent Status of Dupilumab," 2022.
More… ↓
